Miguel A. Villalona MD, FACP

Miguel A. Villalona MD, FACP
ProfessorCollege of Medicinevillalona.1@osu.edu
A455A Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-5068Fax: 614-293-7520
  • Experimental Therapeutics

Current Publications

  • Villalona-Calero MARace and ethnicity in cancer therapy: what have we learned?Clin Pharmacol Ther 95 403-12 4/1/2014
  • Carbone DPOncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.J Clin Invest 124 1582-6 4/1/2014
  • Socinski MACALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer.J Thorac Oncol 9 214-21 2/1/2014
  • Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SWCase of sorafenib-induced thyroid storm.J Clin Oncol 31(16) e262-4 6/1/2013
  • Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
  • Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MAA phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Lung Cancer 79(1) 27-32 1/1/2013
  • Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci GIn vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.AAPS J 15(1) 242-9 1/1/2013
  • Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GAPhase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.Cancer Chemother Pharmacol 71(1) 115-21 1/1/2013
  • Chao BH, Briesewitz R, Villalona-Calero MARET fusion genes in non-small-cell lung cancer.J Clin Oncol 30(35) 4439-41 12/10/2012
  • Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VARandomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.J Clin Oncol 30(17) 2063-9 6/10/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu